Poster-Non-imaging Biomarkers

Poster-Non-imaging Biomarkers

Non-Right-Handedness May be Associated with More Severe Multiple Sclerosis

Background: Because handedness non-right-handedness (NRH) is associated with increased incidence of other auto-immune disorders, Shirani et...

Read More

Poster-Non-imaging Biomarkers

Validating the Clinical Usefulness of the Timed 25-Foot Walk in MS in Routine Clinical Practice

Background: Multiple Sclerosis (MS) is a chronic and degenerative autoimmune disease of the central nervous system which can cause...

Read More

Poster-Non-imaging Biomarkers

Cerebrospinal Fluid Protein Is Higher in Males with Multiple Sclerosis: Results from an International Multicenter Cohort

Background: Sex has a differential effect on MS disease severity. Males tend to have a more severe clinical course and …...

Read More

Poster-Non-imaging Biomarkers

Predicting Stress Levels and Response to a Self-Management Program Using Participant Demographic, Clinical, and Biomarker Data: A Secondary Analysis

Background: Stress management techniques are actively being pursued for multiple sclerosis (MS); the utility of biomarkers for predicting...

Read More

Poster-Non-imaging Biomarkers

Combinatorial Analysis of Plasma and DNA Methylation Biomarkers in African American Patients with Multiple Sclerosis

Background: African American patients are at increased risk of developing severe forms of multiple sclerosis and have been underrepresented...

Read More

Poster-Non-imaging Biomarkers

Concentration of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study

Background: Evobrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...

Read More

Poster-Non-imaging Biomarkers

The Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor targeting B cells and myeloid cells. A phase 2 randomized...

Read More